MSTX (Mast therapeutics) shareholders have been overdue for some good news after the SEP data disaster wiped out nearly 80% of stock value dropping it from the .60s to a range of .10-15.
VAPOLAXOMER* was a novel technology designed by MSTX to help ease sufferers of sickle cell anemia that ultimately was proven ineffective and was abandoned.
Left with only AIR001,...
